Natalizumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00108 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 42 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | bronchitis | KG + DL |
| 2 | parapsoriasis | KG + DL |
| 3 | psoriasis | KG + DL |
| 4 | severe nonproliferative diabetic retinopathy | KG + DL |
| 5 | acute lichenoid pityriasis | KG + DL |
| 6 | pityriasis lichenoides | KG + DL |
| 7 | penile fibromatosis | KG + DL |
| 8 | pustulosis palmaris et plantaris | KG + DL |
| 9 | dermatitis | KG + DL |
| 10 | neonatal dermatomyositis | KG + DL |
| 11 | palmar fibromatosis | KG + DL |
| 12 | Ledderhose disease | KG + DL |
| 13 | acrodermatitis chronica atrophicans | KG + DL |
| 14 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | KG + DL |
| 15 | amyopathic dermatomyositis | KG + DL |
| 16 | acne keloid | KG + DL |
| 17 | infantile digital fibromatosis | KG + DL |
| 18 | psoriasis 14, pustular | KG + DL |
| 19 | hydroa vacciniforme, familial | KG + DL |
| 20 | posterior leukoencephalopathy syndrome | KG + DL |
| 21 | Camurati-Engelmann disease | KG + DL |
| 22 | anus disease | KG + DL |
| 23 | carcinosarcoma | KG + DL |
| 24 | diabetic retinopathy | KG + DL |
| 25 | Crohn disease of the esophagus | KG + DL |
| 26 | functional neutrophil defect | KG + DL |
| 27 | progressive relapsing multiple sclerosis | KG + DL |
| 28 | aortic valve insufficiency | KG + DL |
| 29 | granulomatous disease, chronic, autosomal recessive, 5 | KG + DL |
| 30 | balanitis xerotica obliterans | KG + DL |
| 31 | nephrosclerosis | KG + DL |
| 32 | familial Dupuytren contracture | KG + DL |
| 33 | IgA glomerulonephritis | KG + DL |
| 34 | IgA nephropathy, susceptibility to | KG + DL |
| 35 | seborrheic dermatitis | KG + DL |
| 36 | granulomatous disease with defect in neutrophil chemotaxis | KG + DL |
| 37 | geleophysic dysplasia | KG + DL |
| 38 | Peyronie disease | KG + DL |
| 39 | primary release disorder of platelets | KG + DL |
| 40 | ulcerative colitis (disease) | KG + DL |
| 41 | pseudo-von Willebrand disease | KG + DL |
| 42 | balanoposthitis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.